Key points:
• SUDA enters into a fully funded development, licence and supply agreement with Cann Pharmaceutical Australia Ltd (CPA);
• SUDA will optimise its OroMist® oro-mucosal spray technology to deliver CPA’s pharmaceutical-grade cannabis formulations;
• The product is for the treatment of drug-resistant epilepsy, melanoma and motion sickness throughout the world.
For more information, download the attached PDF.
Download this document
